NASDAQ:EPZM
Delisted
Epizyme Stock News
$1.47
+0 (+0%)
At Close: Nov 10, 2022
Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific Program
12:00am, Wednesday, 13'th May 2020
Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific Program
Mantle Cell Lymphoma Treatment Market - Global Industry to Discern Magnified Growth During 2020-2027
02:40am, Friday, 08'th May 2020
May 07, 2020 (Global QYResearch via COMTEX) --
This report studies the global Mantle Cell Lymphoma Treatment market status and forecast, categorizes the...
Allogene's (ALLO) Q1 Loss Widens Y/Y, Pipeline Progresses
02:51pm, Thursday, 07'th May 2020
Allogene (ALLO) reports no revenues for the first quarter of 2020.
Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program
12:00am, Thursday, 07'th May 2020
Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program
Epizyme's (EPZM) Q1 Earnings Beat Estimates, Revenues Miss
01:11pm, Tuesday, 05'th May 2020
Epizyme (EPZM) reports a narrower-than-expected Q1 loss but misses on revenues.
Oppenheimer Maintains Perform on Epizyme, Raises Price Target to $17
12:51pm, Tuesday, 05'th May 2020Edited Transcript of EPZM earnings conference call or presentation 4-May-20 1:00pm GMT
12:46pm, Tuesday, 05'th May 2020
Q1 2020 Epizyme Inc Earnings Call
Epizyme's (EPZM) Q1 Earnings Beat Estimates, Revenues Miss
12:00am, Tuesday, 05'th May 2020Epizyme Inc (EPZM) Q1 2020 Earnings Call Transcript
11:00pm, Monday, 04'th May 2020
On the call with me is Rob Bazemore, CEO; Matt Ros, Chief Strategy and Business Officer; Dr. Shefali Agarwal, Chief Medical Officer; and Paolo Tombesi, Chief Financial Officer who will join us for the
Epizyme (EPZM) Reports Q1 Loss, Misses Revenue Estimates
11:45am, Monday, 04'th May 2020
Epizyme (EPZM) delivered earnings and revenue surprises of 31.08% and -48.60%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Epizyme: Q1 Earnings Insights
11:04am, Monday, 04'th May 2020
Shares of Epizyme (NASDAQ:EPZM) were unaffected at $15.75 after the company reported Q1 results.Quarterly Results Earnings per share fell 30.77% over the past year to ($0.51), which beat the estimate
Epizyme Q1 EPS $(0.51) Beats $(0.74) Estimate, Sales $1.354M Miss $3.680M Estimate
10:33am, Monday, 04'th May 2020Epizyme Reports Business Progress and First Quarter 2020 Financial Results
10:30am, Monday, 04'th May 2020
Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today provided business and pipeline updates and reported first quarter 2
Epizyme Reports Business Progress and First Quarter 2020 Financial Results
12:00am, Monday, 04'th May 2020
Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today provided business
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
